FDA's enforcement report lists a Class II recall of vancomycin injection 1 g in 200 mL of 5% dextrose in Galaxy single-dose containers from Baxter Healthcare, dated 9 September and ongoing. The stated reason is deviations from current good manufacturing practice.
Class II means use may cause temporary or reversible harm, or serious harm is remote. The record reports no patient injury and does not list lots. This is a US-marketed premixed bag; its availability in India is not stated.
- Ask pharmacy to check premixed vancomycin stock against the FDA listing.
- Switch to pharmacy-prepared vancomycin infusions if stock is withdrawn.
- Continue trough or AUC monitoring as usual.
Why it matters
Premixed vancomycin is a ward staple, and supply gaps affect sepsis treatment timelines.
Don't overread it
A manufacturing-practice recall is not a report of patient harm.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free